Key result
Recurrent ASCVD events link to progressively higher mortality and 1-year recurrence rates reaching ~44%.
Why the study?
To describe the occurrence of recurrent ASCVD events within 3 years after a new-onset event, the associated disease burden, and statin prescribing in patients with ASCVD in Taiwan.
Does the accumulation of recurrent ASCVD events increase the risk of subsequent cardiovascular events, all-cause mortality, and healthcare utilization in patients hospitalized with new-onset CHD, CBVD, or PAD?
Cohort (n=233,029)
Yes
Does the accumulation of recurrent ASCVD events increase the risk of subsequent cardiovascular events, all-cause mortality, and healthcare utilization in patients hospitalized with new-onset CHD, CBVD, or PAD?
In a nationwide Taiwanese cohort of over 233,000 patients with new-onset ASCVD, each recurrent event compounded the risk of further events, mortality, and healthcare utilization, while statin prescribing remained markedly suboptimal across all vascular beds, especially in PAD.
Answers are grounded in this paper and cite their sources.
Recurrent ASCVD signals rising risk; extends observational data on recurrence but leaves optimal interventions open.
OBJECTIVES: To describe the occurrence of recurrent atherosclerotic cardiovascular disease (ASCVD) events within 3 years after a new-onset event, the associated disease burden and statin prescribing in patients with ASCVD in Taiwan. DESIGN: Retrospective cohort study. SETTING: This was a retrospective cohort study using Taiwan's National Health Insurance Research Database. PARTICIPANTS: In total, 111 399, 133 538 and 21 572 patients who were hospitalised with diagnosis of coronary heart disease (CHD), cerebrovascular disease (CBVD) and peripheral artery disease (PAD), respectively, between 1 January 2012 and 31 December 2014. PRIMARY AND SECONDARY OUTCOME MEASURES: For each index and recurrent event, patients were observed for 12 months after admission to quantify risks of mortality, recurrent events, statin treatment and healthcare use. RESULTS: We identified 97 321, 120 914 and 14 794 patients with new-onset CHD, CBVD and PAD, respectively. The proportions of developing first, second and third recurrent events were 22.5%, 25.6% and 30.9% for CHD; 20.9%, 26.2% and 32.4% for CBVD and 40.2%, 41.4% and 43.6% for PAD, respectively. Most patients had the same type of ASCVD for their recurrent events as their new-onset event. The mortality rates increased with each recurrent event (p<0.05 for all three ASCVD groups). The rates of hospital readmission and emergency room (ER) visit increased with increasing recurrent events. For example, in the CHD group, the 1-year readmission rates following the index, first and second recurrent events were 43.1%, 47.6% and 55.3%, respectively, and the proportions of visiting ER were 46.4%, 51.9% and 57.8%, respectively. Statin prescribing was suboptimal at time of index event and recurrent events. CONCLUSION: Recurrent ASCVD events were associated with a higher risk of recurrent event and mortality and greater healthcare use. However, statin prescriptions at index event and after each recurrent event were suboptimal.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2023) conducted a cohort in New-onset atherosclerotic cardiovascular disease (CHD, CBVD, or PAD) (n=233,029). Recurrent atherosclerotic cardiovascular disease (ASCVD) events vs. Index new-onset ASCVD event was evaluated on Recurrent ASCVD events and all-cause mortality within 12 months following index, first, and second recurrent events (p=<0.05). Recurrent ASCVD events were associated with progressively higher 1-year recurrence rates and increased mortality, alongside suboptimal statin use.
Synapse has enriched 10 related papers. Consider them for comparative context: